{
    "clinical_study": {
        "@rank": "144758", 
        "acronym": "TAPAS", 
        "arm_group": [
            {
                "arm_group_label": "Tenofovir to abacavir", 
                "arm_group_type": "Experimental", 
                "description": "Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)"
            }, 
            {
                "arm_group_label": "Abacavir to tenofovir", 
                "arm_group_type": "Experimental", 
                "description": "Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)"
            }
        ], 
        "brief_summary": {
            "textblock": "Some but not all observational studies have found that current exposure to abacavir is\n      associated with increased risk of cardiovascular events such as myocardial infarction,\n      stroke and cardiovascular death. This study aim to investigate possible adverse effect of\n      abacavir on platelet reactivity, coagulation and endothelial activation in HIV-1 infected\n      patients. The study is an open-labeled cross-over trial, where patients receiving\n      antiretroviral therapy containing abacavir switch treatment to a regimen containing\n      tenofovir and vice versa for a period of 90 days."
        }, 
        "brief_title": "Tenofovir Abacavir Platelet Activation Study", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-1 infected\n\n          -  Can understand and sign written informed consent\n\n          -  Received one of the above mentioned antiretroviral regimens continuously \u2265 6 months\n\n          -  HIV RNA < 400 copies/mL for \u2265 6 months\n\n        Exclusion Criteria:\n\n          -  Receiving anticoagulant therapy, adenosine diphosphate (ADP) receptor inhibitors,\n             aspirin or nonsteroidal antiinflammatory drugs (NSAIDs)\n\n          -  Previous ischemic heart disease, peripheral atherosclerotic disease or stroke\n\n          -  Coagulation disorder (e.g. hemophilia, factor V Leiden mutation)\n\n          -  Platelet count < 150 x 109/L during the past 6 months from inclusion\n\n          -  Estimated glomerular filtration rate (eGFR) <70 during the past 6 months from\n             inclusion\n\n          -  Humane leukocyte antigen (HLA)-B*57:01 positive genotype\n\n          -  Hepatitis B or C positive during the past year from inclusion\n\n          -  Hypersensitivity to the active substances or to any of the excipients"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093585", 
            "org_study_id": "2013-001685-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tenofovir to abacavir", 
                "intervention_name": "abacavir (600 mg QD)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Abacavir to tenofovir", 
                "intervention_name": "tenofovir (245 mg QD)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Abacavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV-1", 
            "Abacavir", 
            "Platelet activation", 
            "Thromboelastography", 
            "Coagulation"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "email": "frederikkefr@gmail.com", 
                "last_name": "Frederikke R\u00f6nsholt, MD", 
                "phone": "+45 35459744"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen \u00d8", 
                    "country": "Denmark", 
                    "state": "Copenhagen", 
                    "zip": "2100"
                }, 
                "name": "Rigshospitalet, Klinik for Infektionsmedicin og Reumatologi, 8622"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Changes in Coagulation and Platelet Reactivity in HIV-1 Infected Patients Switching Between Abacavir and Tenofovir Containing Antiretroviral Regimens", 
        "overall_contact": {
            "email": "frederikkefr@gmail.com", 
            "last_name": "Frederikke R\u00f6nsholt, MD", 
            "phone": "+45 35459744"
        }, 
        "overall_official": {
            "affiliation": "Rigshospitalet, Denmark", 
            "last_name": "Jan Gerstoft, MD, DMSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Denmark: The Regional Committee on Biomedical Research Ethics", 
                "Denmark: National Board of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Differences in platelet aggregation (Multiplate) before and after switching between abacavir and tenofovir.", 
                "safety_issue": "No", 
                "time_frame": "before and after 90 days intervention"
            }, 
            {
                "measure": "Differences in clot formation kinetics (thromboelastography) before and after switching between abacavir and tenofovir.", 
                "safety_issue": "No", 
                "time_frame": "before and after 90 days intervention"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093585"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rigshospitalet, Denmark", 
            "investigator_full_name": "Jan Gerstoft", 
            "investigator_title": "MD, DMSc, Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Concentration of plasma lipids", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "activated partial thromboplastin time  (APTT)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "international normalized ratio (INR)/Factor II, VII, X", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Platelet count", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Fibrinogen", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "D-dimer", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Antithrombine", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Interleukin 6 (IL-6)", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "High sensitivity C reactive protein (HS-CRP)", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Soluble P-Selectin", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "soluble CD40 ligand (sCD40L)", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Syndecan-1", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Soluble E-selectin", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }, 
            {
                "measure": "Tissue plasminogen activator", 
                "safety_issue": "No", 
                "time_frame": "Before and after 90 days intervention"
            }
        ], 
        "source": "Rigshospitalet, Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jan Gerstoft", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}